Datamonitor, Nov 2011, Pages: 37
the benefit of add-on therapies.
Features and benefits
- Forecast leading antidyslipidemic brands in the 2010–2020 period
- Quantify the sales potential late-stage pipeline products
- Assess the impact of key
MP Advisors, Jan 2012, Pages: 109
will continue to deliver. 2012 should emerge as strong as 2011 in terms of new approvals.
A very strong positive news-flow on late stage pipeline products in select therapy areas - Melanoma, HCV, Anticoagulants
Datamonitor, Feb 2011
for “blockbuster” sales.
- The late-stage pipeline, much of which is targeting MRSA, will generate revenues totaling nearly $2.0bn by 2019. However, Datamonitor predicts that this upside will be insufficient
Decision Resources, Inc., Dec 2009, Pages: 34
The Targeted Cancer Therapies Pipeline: A Strategic Review The current flurry of research into the development of new drugs against novel cancer targets is unprecedented. Many pharmaceutical
UBM Canon, Nov 2010, Pages: 124
the potential to become blockbuster brands.
Pipelines from the top 15 therapeutic areas are presented in order determined by the total number of products awaiting approval and in clinical trials
UBM Canon, June 2010, Pages: 198
as clinicians are searching for better approaches to target tumors. For instance, a newgeneration of cancer therapeutics are using the immune system. Many emerging cancer treatments have the potential to become
Spectra Intelligence, Nov 2011, Pages: 66
of interest for major pharmaceutical companies, reflecting the view that orphan drugs were specialty products with limited market potential thus offering a poor fit for companies based upon the blockbuster
Business Insights, Feb 2005, Pages: 132
Beyond The Blockbuster Drug: Strategies For Nichebuster Drugs, Targeted Therapies and Personalized Medicine. The blockbuster model now delivers just 5% return on investment and only one in six new
Decision Resources, Inc., March 2011, Pages: 32
the industry’s fascination with exploiting new biologics opportunities.
Corporate goals in this arena increasingly focus on five major strategies: (1) increasing the proportion of biologics in R&D pipelines
Decision Resources, Inc., Dec 2008, Days: 65
Research Laboratories
Taking Advantage of External Innovation
R&D Pipeline
2008 Lessons
Capturing Value with a Vital New Strategic Tool
Lulu Pickering, Ph.D., Senior Program Manager, Spectrum, Pharmaceutical
Datamonitor, Oct 2010, Pages: 196
franchise provides blockbuster vaccine sales for Pfizer
Weaknesses: strong reliance on Prevnar franchise as sole revenue generator
Opportunities: expansion into new geographies and target groups
UBM Canon, Sep 2011, Pages: 234
, in the U.S. and EU as well as FDA approval for generic Enoxaparin. The Swiss company has at least seven more potentialblockbusters in the pipeline.
The following information is included for the top 50
GBI Research, March 2012, Pages: 92
their pipeline products by identifying potential geographies with strong growth.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps.
- Develop key
Frost & Sullivan, Dec 2008, Pages: 88
to mitigate risk, identify new opportunities, and drive effective strategies for growth. For more information on this custom subscription service, please click here.
Market Overview
Niche Blockbusters Offer
GBI Research, Feb 2011, Pages: 100
.
GBI Research finds that TT is the need of the hour for biotech and pharmaceutical companies to recover from the loss of revenue by patent expiry of conventional blockbuster drugs. Thus key pipeline
UBM Canon, Feb 2011, Pages: 68
for pain prevention and treatment continues to garner the attention of R&D managers and other industry executives. Accordingly, potentialnewblockbuster drugs are expected to penetrate the market including
GBI Research, Dec 2009, Pages: 132
market potential in various indications such as rheumatoid arthritis and metastatic NSCLC. In addition, the report provides insights into the monoclonal antibodies R&D pipeline and the potentialblockbusters
Decision Resources, Inc., March 2007, Pages: 29
blockbusters? What lessons does the rate of FDA approval for biologics hold for companies interested in developing new biologics?
- In recent years, the number of monoclonal antibodies (MAbs) under development
GBI Research, Aug 2010, Pages: 125
.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target
Spectra Intelligence, Oct 2009, Pages: 81
of pipeline products for addiction disorders
- Review of promising pipeline products and potential market opportunities
- Extensive coverage of the R&D pipeline for addiction disorders
- Guide to leads
